Compare PNTG & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | OMER |
|---|---|---|
| Founded | 2019 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 894.8M |
| IPO Year | N/A | 2009 |
| Metric | PNTG | OMER |
|---|---|---|
| Price | $29.09 | $11.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $36.50 | $32.50 |
| AVG Volume (30 Days) | 198.0K | ★ 4.4M |
| Earning Date | 02-26-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $847,274,000.00 | N/A |
| Revenue This Year | $36.42 | N/A |
| Revenue Next Year | $23.99 | N/A |
| P/E Ratio | $39.77 | ★ N/A |
| Revenue Growth | ★ 29.89 | N/A |
| 52 Week Low | $21.18 | $2.95 |
| 52 Week High | $30.46 | $17.65 |
| Indicator | PNTG | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 47.41 |
| Support Level | $28.21 | $11.85 |
| Resistance Level | $29.00 | $13.26 |
| Average True Range (ATR) | 0.91 | 1.32 |
| MACD | -0.02 | -0.46 |
| Stochastic Oscillator | 55.06 | 4.22 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.